Clinical Trial Update: Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Actovegin given IV then oral for peripheral arterial occlusive disease (Fontaine IIB) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Arterial Occlusive Disease

Drugs mentioned

• Actovegin

Snippet

Sponsor: Takeda | Conditions: Peripheral Arterial Diseases | Phase 3 | Status: COMPLETED | Results posted: 2020-10-28